The disease is happening in the shadows
Tuberculosis has long been one of humanity's most enduring adversaries, and India stands at the center of that struggle — carrying a disproportionate share of the global burden while attempting something historically ambitious: not merely managing the disease, but eliminating it. The country's transition to the National Tuberculosis Elimination Program marks a philosophical shift from containment to eradication, one that has produced measurable gains in detection and treatment. Yet the path between progress and elimination is crowded with obstacles — drug-resistant strains, the compounding tragedy of HIV co-infection, a largely unregulated private medical sector, and the lingering disruptions of a pandemic — each reminding us that disease is never only a medical problem, but a mirror of the social and structural conditions in which people live.
- India bears one of the world's heaviest tuberculosis burdens, and drug-resistant strains are emerging faster than standard treatment protocols can contain them.
- Thousands of private clinics treat TB patients outside the national program's reach, creating invisible reservoirs of infection where incomplete or improper treatment quietly breeds resistance.
- The COVID-19 pandemic fractured the rhythms of diagnosis and reporting, leaving an unknown number of TB cases undetected and untreated during a critical window.
- HIV co-infection compounds the challenge further, producing patients whose cases are harder to cure, easier to miss, and more dangerous to those around them.
- India's elimination program has achieved real gains in detection and treatment outcomes, but those gains remain uneven — strongest where infrastructure exists, weakest where it is needed most.
- Closing the gap requires not just medical intervention but investment in rural infrastructure, poverty reduction, and binding the private sector into national surveillance and standards.
Tuberculosis kills more people than almost any other infectious disease on earth, and India carries an outsized share of that weight. In response, the country has made a fundamental strategic shift — moving from the older disease-management mindset of the Revised National Tuberculosis Control Program toward the more ambitious National Tuberculosis Elimination Program, which aims not just to treat cases but to break the chain of transmission entirely. The results have been real: case detection has improved, treatment outcomes have advanced, and the diagnostic infrastructure has grown more capable across many regions.
But progress and peril occupy the same space. Drug-resistant tuberculosis continues to spread, defying standard medications and demanding far more complex care. Patients living with both TB and HIV face compounded medical challenges that existing protocols struggle to meet. These are not peripheral complications — they are structural threats to any elimination strategy, representing cases that are harder to cure, more likely to be missed, and more likely to infect others.
Equally consequential is the gap hidden within India's vast private healthcare sector. Thousands of clinics and practitioners treat TB patients with minimal coordination with national programs and little adherence to standardized protocols. Patients may receive incomplete treatment, inadvertently developing resistance, and then disappear from any public health record. The elimination strategy is, in effect, trying to map a disease that is partly living in the dark.
The COVID-19 pandemic deepened these vulnerabilities. TB notification rates fell during lockdowns — not because the disease retreated, but because people couldn't reach clinics and health systems were overwhelmed. Many of those missed cases were never recovered. The disruption exposed how dependent the entire system is on consistent access and unbroken operation.
A new analysis in the Zoonoses journal traces this evolution and names what remains undone. India has demonstrated it can improve TB care at scale. What it has not yet achieved is the reach and consistency to do so everywhere — in rural clinics, in private offices, in the communities where poverty, malnutrition, and crowded housing give the disease its deepest footholds. The tools exist. The question is whether the capacity to deploy them universally can be built before the window for elimination narrows further.
Tuberculosis kills more people than almost any other infectious disease on the planet, and India carries an outsized share of that burden. The country's TB cases represent a substantial portion of the global total—a reality that has shaped public health strategy for decades. But in recent years, India's approach has undergone a fundamental shift: the focus has moved from simply controlling TB to actually eliminating it.
That ambition is reflected in the transition from the Revised National Tuberculosis Control Program, which operated for years with a disease-management mindset, to the newer National Tuberculosis Elimination Program. The change is more than semantic. It signals a commitment to not just treating cases as they arise, but to breaking the chain of transmission entirely. And there have been real gains. Case detection has improved. Treatment outcomes have gotten better. The machinery of diagnosis and care has become more efficient in many parts of the country.
Yet progress and obstacles exist in the same space. Drug-resistant tuberculosis—strains that shrug off standard medications—continues to emerge and spread. Patients who carry both TB and HIV face compounded medical challenges that standard protocols struggle to address. These are not minor complications. They are fundamental threats to any elimination strategy, because they represent cases that are harder to cure, more likely to transmit, and more likely to be missed by surveillance systems.
There is another gap, less visible but equally consequential: the private medical sector. India's healthcare landscape includes thousands of private clinics, hospitals, and practitioners who treat TB patients outside the public system. Many of these providers operate with minimal oversight, minimal coordination with national programs, and minimal adherence to standardized treatment protocols. A patient might receive incomplete treatment, or treatment that breeds resistance, and that person becomes a vector for further spread. The public health system has no way to track them. The elimination strategy, in other words, is trying to hit a target while a significant portion of the disease is happening in the shadows.
The COVID-19 pandemic added another layer of disruption. TB notification rates dropped during lockdowns and surges, not because TB disappeared but because people couldn't access clinics, because health systems were overwhelmed, because the normal rhythms of diagnosis and reporting fractured. Some of those cases were eventually found. Many were not. The pandemic exposed how fragile the infrastructure remains, how dependent the system is on consistent access and continuous operation.
India's TB elimination goals are not impossible. The country has demonstrated it can improve detection and treatment at scale. But the path forward requires addressing problems that are not purely medical. Operational capacity needs to expand. Infrastructure in rural and underserved areas needs investment. The socioeconomic conditions that allow TB to flourish—poverty, malnutrition, crowded housing—need to be tackled alongside the disease itself. And the private sector, which treats a significant share of TB patients, needs to be brought into alignment with national standards and surveillance.
A new article in the Zoonoses journal examines these dynamics in detail, tracing India's TB control evolution and laying out what remains to be done. The picture it presents is one of genuine progress shadowed by persistent gaps. India has the tools and the programs. What it needs now is the capacity to deploy them everywhere, and the ability to see and treat every case, whether it emerges in a public clinic or a private one.
The Hearth Conversation Another angle on the story
Why does India's TB burden matter so much to the global picture?
India accounts for a huge share of the world's TB cases. When you're trying to eliminate a disease globally, you can't ignore the places where it's most concentrated. India is one of those places.
The shift from control to elimination—what's the actual difference in how you approach the work?
Control means managing the disease, treating cases as they come. Elimination means breaking transmission entirely. It's the difference between maintaining a system and ending the problem.
But you said there's been progress. What does that actually look like?
Better case detection, better treatment outcomes. The machinery works better than it did. More people are being found and cured.
Then what's blocking the path forward?
Drug-resistant strains that don't respond to standard drugs. TB patients who also have HIV, which complicates everything. And a huge private sector that operates outside the public system—no oversight, no coordination, no way to track what's happening.
The private sector sounds like a blind spot.
It is. Thousands of private clinics treating TB patients with no standardized protocol, no reporting to national programs. A patient gets incomplete treatment, develops resistance, spreads it further. The public health system never sees it.
What did COVID do to all this?
It fractured the system. TB notification dropped not because TB went away, but because people couldn't access care. Some cases were found later. Many weren't. It showed how dependent everything is on consistent access.